VIPoma natural history, complications and prognosis: Difference between revisions
Madhu Sigdel (talk | contribs) No edit summary |
Madhu Sigdel (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{MSI}}{{PSD}} | {{CMG}}{{AE}}{{MSI}}{{PSD}} | ||
==Overview== | ==Overview== | ||
If left untreated, patients with VIPoma may progress to develop watery [[diarrhea]], [[abdominal pain]], [[bloating]], [[nausea]], [[vomiting]], [[skin rash]], [[backache]], [[flushing]], and [[lethargy]].<ref name="NatanziAmini2009">{{cite journal|last1=Natanzi|first1=Naveed|last2=Amini|first2=Mazyar|last3=Yamini|first3=David|last4=Nielsen|first4=Shawn|last5=Ram|first5=Ramin|title=Vasoactive Intestinal Peptide Tumor|journal=Scholarly Research Exchange|volume=2009|year=2009|pages=1–7|issn=1687-8299|doi=10.3814/2009/938325}}</ref> Common complications of VIPoma include [[metastasis]], [[cardiac arrest]] from low blood [[potassium]] level, and [[dehydration]]. The presence of metastasis is associated with a particularly poor prognosis among patients with VIPoma, with a 5 year survival rate of | If left untreated, patients with VIPoma may progress to develop watery [[diarrhea]], [[abdominal pain]], [[bloating]], [[nausea]], [[vomiting]], [[skin rash]], [[backache]], [[flushing]], and [[lethargy]].<ref name="NatanziAmini2009">{{cite journal|last1=Natanzi|first1=Naveed|last2=Amini|first2=Mazyar|last3=Yamini|first3=David|last4=Nielsen|first4=Shawn|last5=Ram|first5=Ramin|title=Vasoactive Intestinal Peptide Tumor|journal=Scholarly Research Exchange|volume=2009|year=2009|pages=1–7|issn=1687-8299|doi=10.3814/2009/938325}}</ref> Common complications of VIPoma include [[metastasis]], [[cardiac arrest]] from low blood [[potassium]] level, and [[dehydration]]. The presence of metastasis is associated with a particularly poor prognosis among patients with VIPoma, with a 5 year survival rate of 60%.<ref name="pmid27583474" /> | ||
==Natural History== | ==Natural History== | ||
Revision as of 15:46, 5 January 2018
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of VIPoma natural history, complications and prognosis |
|
VIPoma natural history, complications and prognosis in the news |
|
Blogs on VIPoma natural history, complications and prognosis |
|
Risk calculators and risk factors for VIPoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3]
Overview
If left untreated, patients with VIPoma may progress to develop watery diarrhea, abdominal pain, bloating, nausea, vomiting, skin rash, backache, flushing, and lethargy.[1] Common complications of VIPoma include metastasis, cardiac arrest from low blood potassium level, and dehydration. The presence of metastasis is associated with a particularly poor prognosis among patients with VIPoma, with a 5 year survival rate of 60%.[2]
Natural History
- If left untreated, patients with VIPoma may progress to develop watery diarrhea, abdominal pain, bloating, nausea, vomiting, skin rash, backache, flushing, and lethargy.[1]
- VIPoma have a very slow growth rate compared to most malignant tumors.
Complications
Common complications of VIPoma include:
- Metastasis
- Cardiac arrest from low blood potassium level
- Dehydration
Prognosis
- Surgery can usually cure VIPomas. However, in one-third to one-half of patients, the tumor has spread by the time of diagnosis and cannot be cured.
- The 5-year survival for patients with localized VIPoma is 94% whereas metastatic pancreatic VIPomas is 60%, respectively.[2]
References
- ↑ 1.0 1.1 Natanzi, Naveed; Amini, Mazyar; Yamini, David; Nielsen, Shawn; Ram, Ramin (2009). "Vasoactive Intestinal Peptide Tumor". Scholarly Research Exchange. 2009: 1–7. doi:10.3814/2009/938325. ISSN 1687-8299.
- ↑ 2.0 2.1 Nilubol N, Freedman EM, Quezado MM, Patel D, Kebebew E (2016). "Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report". J Clin Endocrinol Metab. 101 (10): 3564–3567. doi:10.1210/jc.2016-2051. PMC 5052354. PMID 27583474.